• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢综合征及其相关生化紊乱在接受新辅助化疗的乳腺癌患者中的表现:来自印度南部 Puducherry 一家三级肿瘤中心的研究。

Metabolic syndrome and its related biochemical derangements in breast cancer patients who received neoadjuvant chemotherapy: A study from a tertiary care oncology centre from Puducherry, South India.

机构信息

Department of Biochemistry, JIPMER, Puducherry, India.

Department of Biochemistry, JIPMER, Puducherry, India.

出版信息

Diabetes Metab Syndr. 2021 May-Jun;15(3):975-980. doi: 10.1016/j.dsx.2021.04.022. Epub 2021 Apr 27.

DOI:10.1016/j.dsx.2021.04.022
PMID:33962149
Abstract

BACKGROUND AND AIMS

Comparison of the existence of metabolic syndrome, its components and their related biochemical complications between newly diagnosed and treated breast cancer patients.

METHODS

Forty newly diagnosed untreated breast cancer patients and forty breast cancer patients who had received 7 cycles of neoadjuvant chemotherapy were recruited as group 1 and group 2 respectively. Height, weight, blood pressure, hormonal status, and tumor size were noted. The fasting blood glucose and lipid profile were estimated in AU 5811 Beckman coulter Clinical chemistry analyzer. Fasting insulin was estimated using Beckman Coulter access immunoassay system (UnicelDxI600). HbA1c assay was carried out in HPLC based ion exchange chromatography (Tosoh automated glycohemoglobin analyzer G8. Homeostasis Model Assessment 2-IR (HOMA 2-IR), HOMA-% B and HOMA-% S were calculated using an online calculator HOMA CALCULATOR [Oxford University]. Serum hsCRP and MDA were estimated by ELISA. FRAP assay was carried out manually to measure antioxidant status.

RESULTS

The existence of metabolic syndrome as well as type 2 diabetes was higher in the treated group when compared to the untreated patients. However, there were no significant differences in the indices of glucose homeostasis, low grade inflammation, oxidative stress and individual components of metabolic syndrome between the two groups. The triple negative patients were more prone to develop metabolic syndrome when compared to the triple positive patients.

CONCLUSION

Suitable therapeutic approaches may be planned out to address the metabolic syndrome and its related complications among breast cancer patients especially during the course of treatment.

摘要

背景与目的

比较新诊断和治疗的乳腺癌患者中代谢综合征的存在、其组成部分及其相关生化并发症。

方法

招募 40 名新诊断未经治疗的乳腺癌患者和 40 名接受了 7 个周期新辅助化疗的乳腺癌患者分别作为第 1 组和第 2 组。记录身高、体重、血压、激素状态和肿瘤大小。使用 AU 5811 Beckman coulter 临床化学分析仪评估空腹血糖和血脂谱。使用 Beckman Coulter access immunoassay 系统(UnicelDxI600)估计空腹胰岛素。HbA1c 测定采用基于 HPLC 的离子交换色谱法(Tosoh 自动化糖化血红蛋白分析仪 G8)。使用在线计算器 HOMA CALCULATOR [Oxford University]计算稳态模型评估 2-IR(HOMA 2-IR)、HOMA-%B 和 HOMA-%S。通过 ELISA 估计血清 hsCRP 和 MDA。手动进行 FRAP 测定以测量抗氧化状态。

结果

与未治疗患者相比,治疗组代谢综合征以及 2 型糖尿病的存在更高。然而,两组之间的葡萄糖稳态、低度炎症、氧化应激和代谢综合征的各个组成部分的指数没有显著差异。与三阳性患者相比,三阴性患者更容易发生代谢综合征。

结论

可以制定适当的治疗方法来解决乳腺癌患者的代谢综合征及其相关并发症,尤其是在治疗过程中。

相似文献

1
Metabolic syndrome and its related biochemical derangements in breast cancer patients who received neoadjuvant chemotherapy: A study from a tertiary care oncology centre from Puducherry, South India.代谢综合征及其相关生化紊乱在接受新辅助化疗的乳腺癌患者中的表现:来自印度南部 Puducherry 一家三级肿瘤中心的研究。
Diabetes Metab Syndr. 2021 May-Jun;15(3):975-980. doi: 10.1016/j.dsx.2021.04.022. Epub 2021 Apr 27.
2
An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy.一项观察性研究,旨在检测接受新辅助或辅助化疗的乳腺癌患者代谢综合征各组分的变化。
Cancer. 2016 Sep 1;122(17):2646-53. doi: 10.1002/cncr.30104. Epub 2016 May 24.
3
Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?胰岛素抵抗是接受新辅助治疗的乳腺癌患者完全缓解的预测指标吗?
World J Surg Oncol. 2020 Sep 9;18(1):242. doi: 10.1186/s12957-020-02019-y.
4
Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid.与使用丙戊酸治疗的癫痫患者代谢综合征相关的生化紊乱。
Seizure. 2018 Aug;60:57-60. doi: 10.1016/j.seizure.2018.06.003. Epub 2018 Jun 5.
5
Relationship Between Metabolic Syndrome and Postmenopausal Breast Cancer.代谢综合征与绝经后乳腺癌的关系。
Cir Esp (Engl Ed). 2020 Nov;98(9):540-546. doi: 10.1016/j.ciresp.2019.12.015. Epub 2020 Mar 18.
6
Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study.早期乳腺癌幸存者的关键代谢参数显著变化:一项探索性 PILOT 研究。
J Transl Med. 2019 Apr 1;17(1):105. doi: 10.1186/s12967-019-1850-2.
7
The association between metabolic syndrome components, low-grade systemic inflammation and insulin resistance in non-diabetic Indonesian adolescent male.非糖尿病的印度尼西亚青春期男性中代谢综合征成分、低度系统性炎症与胰岛素抵抗之间的关联。
Clin Nutr ESPEN. 2020 Feb;35:69-74. doi: 10.1016/j.clnesp.2019.12.001. Epub 2020 Jan 1.
8
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.发展中国家乳腺癌新辅助化疗的实际情况:来自印度一家三级癌症中心的 80 例乳腺癌报告。
J Cancer Res Clin Oncol. 2014 Oct;140(10):1777-82. doi: 10.1007/s00432-014-1724-1. Epub 2014 Jun 4.
9
Value of simple clinical parameters to predict insulin resistance among newly diagnosed patients with type 2 diabetes in limited resource settings.在资源有限的环境下,用于预测新诊断 2 型糖尿病患者胰岛素抵抗的简单临床参数的价值。
PLoS One. 2021 Mar 31;16(3):e0248469. doi: 10.1371/journal.pone.0248469. eCollection 2021.
10
The relationship of insulin resistance and metabolic syndrome with known breast cancer prognostic factors in postmenopausal breast cancer patients.绝经后乳腺癌患者中胰岛素抵抗和代谢综合征与已知乳腺癌预后因素的关系。
J BUON. 2013 Oct-Dec;18(4):845-50.

引用本文的文献

1
Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy.2型糖尿病患者三阴性乳腺癌的最新进展:从危险因素到诊断、生物标志物及治疗
Diagnostics (Basel). 2023 Jul 17;13(14):2390. doi: 10.3390/diagnostics13142390.